Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Jack Gallagher

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

J.R. Gallagher1, K.J. Heap2, S. Carroll3

Author affiliations

  • 1 Department Of Analytics, Clarity Pharma Research, LLC, 29307 - Spartanburg/US
  • 2 Research Management, Clarity Pharma Research, LLC, 29307 - Spartanburg/US
  • 3 -, Clarity Pharma Research, LLC, 29307 - Spartanburg/US
More

Resources

Abstract 4190

Background

Niraparib (Zejula®) is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2 inhibitor that has demonstrated efficacy in patients with platinum-sensitive, recurrent ovarian cancer. Nausea, thrombocytopenia, and fatigue were commonly occurring adverse events (AEs) in the phase 3 clinical trial in which patients were started at 300 mg daily dose of niraparib. After dose adjustments in this trial, a daily dose of 200 mg was the most commonly administered dose. This analysis provides a description of AEs among patients receiving an initial dose of 200 mg niraparib.

Methods

In a retrospective observational patient study, 53 randomly selected study-qualified physicians from a national database (61% of qualified physicians screened) extracted requested anonymous information from the medical charts of 153 qualified patients. Qualified patients had received a starting dose of 200 mg/day niraparib for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and were in complete or partial response to platinum-based chemotherapy.

Results

Of the 153 patients, 56 (37%) experienced at least one of the three AEs evaluated within the first three months after niraparib initiation, and 49 (32%) experienced only grades 1/2 AEs. Among the 153 patients, fatigue was reported for 24% (36/153) (CI 17.4% - 31.0%); nausea for 16% (25/153) (CI 10.5% - 22.2%) and thrombocytopenia for 14% (21/153) (CI 8.3% - 19.2%). Of the 21 patients with thrombocytopenia, 3 were grade 3/4 severity (2% of overall). Among the patients, 4% (6/153) had a dose interruption, 11% reduced their dose (17/153), and 2% discontinued niraparib altogether (3/153) due to AEs.

Conclusions

While over 60% of patients in the phase 3 clinical trial reported experiencing the three AEs observed in the study, only 37% reported such in real-world usage. This difference may be due to the higher dosing in the trial study (initial dose of 300 mg/day vs. 200 in the observational study). Additional real-world research is needed to understand the effects of niraparib dosing on AEs.

Clinical trial identification

Legal entity responsible for the study

Clarity Pharma Research, LLC.

Funding

Tesaro, Inc.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

VSV-IFN_-NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Presenter: Steven Powell

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).

Presenter: Cinta Hierro

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings